http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2199642-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8be6a6c990669567cc455d32b00535e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
filingDate 1997-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43028f51c249207d4a5eed0526c52097
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5582ebcf6d927e9dadbf09cfb2e7882f
publicationDate 1998-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2199642-A1
titleOfInvention Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
abstract The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in association with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty. The subject of the invention is moreover pharmaceutical compositions for the treatment or prophylaxy of thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty, comprising the association of an effective quantity of at least one synthetic oligosaccharide, which is a selective inhibitor of factor Xa acting via antithrombin III, and of an effective quantity of aspirin, optionally mixed with one or more pharmaceutically acceptable excipients.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6794412-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005509007-A
priorityDate 1997-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID304917
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ03352
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID540261
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11905
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81050
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556224
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP32261
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ5R5A3
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP41361
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP32262
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01008
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID462

Total number of triples: 30.